Cáncer de mama metastásico: Caracterización de una cohorte según subtipos / Survival of patients with metastatic breast cancer according to pathological types of tumors
We obtained clinical and pathological data from patients diagnosed with a metastatic BC between 1999 and 2013. The expression of estrogen (ER) and progesterone (PR) receptors and humanepidermal growth factor receptor 2 (HER2) was determined by immunohistochemistry. Clinicopathological subtypes were defined as Luminal A ER or PR positive, HER2 negative, histological grade (HG) 1 or 2; Luminal B ER or PR positive, HER2 negative or positive or HG 3; triple negative (TN) ER, PR and HER2 negative, independent of the HG, positive HER2 ER, PR negative and HER2 positive, independent of HG. We analyzed survival based on these subtypes.
Results:
We identified 54 patientsaged 24 to 85 years, with metastatic BC at diagnosis. Seventy five percent had luminaltumors; 19.6% HER2 positive and 7.8% were TN. In 61% of evaluable tumors, HG was classified as 3. The frequency of HER2 positive and high HG tumors was greater in these patients with metastatic BC than in a non-metastatic local BC cohort. Survival was higher among patients with Luminaltumors than in women with non-Luminalcancer (56.4 and 11.4 months, respectively, p = 0.04).